Lilly agreed to acquire Sigilon for $14.92/share upfront cash (~$34.6M) plus a CVR of up to $111.64/share for total potential consideration up to $309.6M. Builds on the Lilly-Sigilon collaboration since 2018 on encapsulated cell therapies including SIG-002 for T1D. Closed August 14, 2023.